ArticleEuropean journal of nuclear medicine and molecular imaging2026
Exploring synaptic density patterns in cerebral small vessel disease: insights from [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeCognitive dysfunction caused by cerebral small vessel disease (CSVD) is the most common cause of vascular dementia. [18F]SynVesT-1 is a promising PET tracer binding Synaptic vesicle glycoprotein 2 A (SV2A) which is a potential biomarker for CSVD diagnosis. This study aimed to discern distinct synaptic density patterns associated with CSVD using [18F]SynVesT-1 PET, and to elucidate the correlation between synaptic density and cognitive performance.
methodsSixteen CSVD patients and ten age- and sex-matched healthy controls (HCs) underwent [18F]SynVesT-1 PET imaging to quantify synaptic density. Comparative analyses were conducted between CSVD and HCs, as well as within different CSVD subgroups based on burden scores and cognitive status. Moreover, associations between regional synaptic density and neuropsychological assessment outcomes in CSVD patients were explored.
resultsCSVD patients exhibited decreased [18F]SynVesT-1 uptake in the bilateral hippocampus-insula region and the left postcentral gyrus compared to HCs (P < 0.001, cluster size > 50). Neuropsychological performance correlated with regional standardized uptake values (P < 0.05). Specifically, CSVD patients with burden scores of 0–1 demonstrated reduced synaptic density in the left insula and lingual gyrus compared to HCs. Conversely, patients with burden scores of 2–4 manifested diminished uptake in the bilateral insula, left parahippocampal gyrus, and right anterior cingulate and paracingulate gyri (P < 0.001, cluster size > 50). Moreover, CSVD patients without cognitive impairment exhibited decreased uptake in the left hippocampus-insula region relative to HCs, while those with cognitive impairment displayed synaptic loss in the bilateral insula, left hippocampus, and anterior cingulate and paracingulate gyri (P < 0.001, cluster size > 50). DISCUSSION: This study represents the first in vivo investigation of synaptic density in CSVD utilizing [18F]SynVesT-1 PET imaging. Our findings suggest the potential of synaptic density as a biomarker for diagnosing CSVD and assessing cognitive impairment and disease progression.
Indexed as
Identifiers
41703298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.